Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advance...
First combination regimen to demonstrate improvement in DFS compared to KEYTRUDA monotherapy for these patients in the adjuvant...
First treatment regimen to demonstrate a statistically significant improvement in PFS for patients whose disease progressed fol...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration...
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administra...
